Technology

Dynamic Cross Linking (DXL™) Technology, Antibodies with Increased Avidity

Our primary platform technology is Dynamic Cross Linking (DXL™), which involves modification or design of antibodies with increased avidity and concomitant increases in complement dependent and cell dependent effector functions without altering affinity or specificity, thereby circumventing any new (unwanted or harmful) cross-reactions with unintended targets. Put simply: DXL™ results in safer antibodies with a higher level of therapeutic usefulness.



DXL antibodies have been shown, for example, to have increased ability to mediate non-effector killing of target tumor cells via apoptosis. For antibodies used in oncology, this means better killing of target tumors, and an ability to use less drug product versus an unmodified antibody. DXL antibodies have the potential to overcome resistance to certain widely used therapeutic antibodies by use of mechanisms not employed by the unmodified antibody. Studies of DXL625 (CD20) for the prospective treatment of non-Hodgkins Lymphoma for example, revealed no toxicity or immunogenicity in primates compared to a non-DXL control antibody, which confirmed results that were earlier indicated in smaller animal studies.


Technical References:

InNexus' Presentation at the 2009 American Association for Cancer Research (AACR) Annual Meeting in Denver, Colorado:

- InNexus' 2009 AACR Scientific Poster - DXL™
- InNexus' 2009 AACR Scientific Poster - WOX


InNexus' Presentation at the 2008 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California:

- InNexus' 2008 AACR Scientific Abstract
- InNexus' 2008 AACR Scientific Poster
- InNexus' 2008 AACR Scientific Data Presentation


Apply InNexus Technology to Your Product

DXL is a robust, patented, platform-breadth technology, which has been consistently shown to develop antibodies with potential for expanded uses in both therapeutic and diagnostic applications. DXL antibodies are being tested for use in oncology, autoimmune disorders and infectious diseases. Increased efficacy with no unexpected immunogenicity or toxicity has been seen in all cases. In addition, antibodies used for diagnostic purposes can give significant increases in signal to background when DXL technology is applied. Let us put the DXL technology to work for your antibody.


Could your antibody function be enhanced with greater efficacy and improved safety as an intracellular or transdermal agent? Contact us to discuss how we can help improve and potentially add a wide range of applications to your antibody products.